Back to Peptide Library
Experimental Exercise Mimetic

SLU-PP-332

Pan-ERR Agonist • Synthetic Small Molecule

SLU-PP-332 is a synthetic small molecule—not a peptide—that activates estrogen-related receptors involved in mitochondrial and exercise-responsive metabolism. Published efficacy findings come from cells and mice, not living human trials.

Routes
Oral / sublingual
Compound type
Small molecule
Regulatory status
Not FDA approved
Last reviewed
At a glance

SLU-PP-332 Quick Reference

Evidence stage
Preclinical
Cell and mouse studies; no published living-human trial
Community formats
Oral / sublingual
Human exposure from these products is unquantified
Community range
Members only
Sign in to view dosing details.
Research target
ERRα / β / γ
Nuclear receptors regulating oxidative metabolism
Overview

What Is SLU-PP-332?

SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα, ERRβ, and ERRγ), with prominent ERRα activity. Despite the name, these receptors do not bind estrogen. The compound is a small molecule, not a peptide.

Researchers studied it as a way to activate parts of the exercise-responsive gene program. In mouse work, improved running capacity and metabolic signals followed laboratory dosing. These findings do not establish a human effect or a useful oral regimen.

Mechanism

SLU-PP-332 Mechanism of Action

Pan-ERR activation

Cell assays show activation of ERRα, ERRβ, and ERRγ, nuclear receptors involved in metabolic gene expression.

Exercise-responsive genes

ERR signaling influences transcription programs associated with oxidative muscle function and adaptation to aerobic activity.

Fuel use and mitochondria

Mouse and cell studies found shifts in fatty-acid oxidation, mitochondrial function, and cellular respiration.

Limited exercise mimicry

One pathway can reproduce selected molecular responses, but it cannot substitute for the full systemic benefits of physical training.

Research findings

SLU-PP-332 Benefits

The reported outcomes are from cells and mice. No published living-human trial has established improved endurance, weight, organ function, or safety. Exercise study · Metabolic study.

Current evidence level: preclinical

Exercise capacity in mice

After repeated laboratory dosing, mice ran about 70% longer and 45% farther than controls in one study.

Weight in obese mice

A 28-day model reported roughly 12% lower body weight without reduced food intake.

Oxidative muscle program

ERR activation increased markers of mitochondrial activity and oxidative muscle characteristics.

Metabolic measures

Mouse studies reported changes in fat oxidation, glucose tolerance, and insulin sensitivity.

Kidney research

Aging-mouse work reported improved albuminuria and selected mitochondrial and inflammatory measures.

Cardiac research

In pressure-overload mice, ERR agonist treatment improved selected heart-function and fibrosis measures.

Protocol planning

SLU-PP-332 Dosing Protocol

Members Access Only

Sign in or create a free account to view this content.

N=1 reports

SLU-PP-332 Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive reports

  • Endurance. Some describe better exercise tolerance or training focus.
  • Body composition. A minority report gradual changes over several weeks.
  • Recovery. Improved training recovery appears in some anecdotes.

Negative reports

  • No noticeable effect. Many reports describe no meaningful change.
  • Inconsistent formats. Capsules and sublingual products produce mixed accounts.
  • Tolerability. Fatigue, disturbed sleep, GI discomfort, or a higher pulse are occasionally reported.
Stacking & synergy

SLU-PP-332 Stacking & Synergy

These are mechanistic comparisons, not validated combinations. No human study has established benefit or safety for stacking SLU-PP-332.

SLU-PP-332 + Semaglutide

ERR and GLP-1 pathways differ, but combined effects and safety have not been tested.

SLU-PP-332 + MOTS-c

AMPK-related and ERR signaling make this a research question; no combination evidence exists.

SLU-PP-332 + SS-31

The compounds address different aspects of mitochondrial biology, but their pairing remains unstudied.

Safety notes

SLU-PP-332 Side Effects & Safety

No published living-human safety trial defines adverse-event rates, drug interactions, or long-term organ effects. Short animal studies cannot establish chronic safety.

The main safety issue is uncertainty: human exposure, metabolism, reproductive effects, cancer risk, and sustained ERR activation remain unstudied.

Published evidence limits

  • No systematic human adverse-event data.
  • HDL cholesterol fell in one metabolic-syndrome mouse study.
  • No established chronic organ or reproductive safety profile.

Community-reported concerns

  • Fatigue, sleep changes, or gastrointestinal discomfort.
  • Feeling unusually winded or a higher heart rate during exercise.
  • Possible blood-sugar drops, especially with fasting or glucose-lowering compounds.

Reports are anecdotal; frequency and causality cannot be determined.

SLU-PP-332 Precautions

Avoid unsupported assumptions
  • Do not interpret mouse findings as proven human benefits.
  • Do not treat bacteriostatic water as a valid reconstitution method.
  • Pregnancy and breastfeeding safety are unknown.
Conditions needing caution
  • Glucose-lowering medications, diabetes, or episodes of low blood sugar.
  • Cardiovascular disease or unexplained exercise intolerance.
  • Kidney or liver impairment, or a history of malignancy, because human effects are unknown.
Regulatory status: SLU-PP-332 is investigational and has no FDA-approved human use.
Final verdict

Peptide Protocols Verdict on SLU-PP-332

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion

On paper, SLU-PP-332 is interesting. In our experience, the products sold to early buyers often came in tiny 250–500 mcg capsules that delivered little noticeable value. Larger 20 mg capsules improved that mismatch, but the cost remains hard to justify when absorption is uncertain and no human safety data exist.

We tested it and would not buy it again. The newer SLU-PP-915 was developed with improved oral activity in mice, highlighting the practical limitation of the original compound. SLU-PP-332 remains useful research chemistry, but for community use its uncertain exposure, high cost, and evidence gap support our D grade.